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a b s t r a c t
Ascorbate (Asc) has been shown to increase nitric oxide (NO) bioavailability and thereby improve endo-
thelial function in patients showing signs of endothelial dysfunction. Tetrahydrobiopterin (BH4) is a co-
factor of endothelial nitric oxide synthase (eNOS) which may easily become oxidized to the inactive form
dihydrobiopterin (BH2). Asc may increase NO bioavailability by a number of mechanisms involving BH4
and eNOS. Asc increases BH4 bioavailability by either reducing oxidized BH4 or preventing BH4 from
becoming oxidized in the ﬁrst place. Asc could also increase NO bioavailability in a BH4-independent
manner by increasing eNOS activity by changing its phosphorylation and S-nitrosylation status or by
upregulating eNOS expression. In this review, we discuss the putative mechanisms by which Asc may
increase NO bioavailability through its interactions with BH4 and eNOS.
 2013 Elsevier Inc. All rights reserved.
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Introduction
Tetrahydrobiopterin (Fig. 1) is an endogenous co-factor of eight
human enzymes: four aromatic amino acid hydroxylases, three ni-
tric oxide synthases and alkylglycerol monooxygenase [1]. The
three nitric oxide synthases (NOS) are neuronal NOS (nNOS or
NOS1), inducible NOS (iNOS or NOS2) and endothelial NOS (eNOS
or NOS3). NOS produces the vaso-relaxing factor nitric oxide
(NO) in a process involving conversion of L-arginine to L-citrulline,
and tetrahydrobiopterin is thus important for regulating blood
pressure. The active form of NOS producing NO is dimeric and
one of the roles of tetrahydrobiopterin is to stabilize this dimer [2].
Biopterin exists in three stable oxidation states: tetrahydrobi-
opterin (BH4), dihydrobiopterin (BH2) and biopterin. Besides these,
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unstable short-lived intermediates such as the trihydrobiopterin
radical and quinoid dihydrobiopterin exist. The most reduced form,
BH4, is easily oxidized to a quinoid form of BH2, qBH2, which rap-
idly rearranges to BH2; BH2 may then be further oxidized to biop-
terin. However, in contrast to BH4, BH2 is relatively stable and is
only slowly oxidized [3].
BH4 and BH2 have been shown to bind to eNOS with similar
afﬁnity (Kd  80 nM) [4]. However, while binding of BH4 to NOS
leads to formation of NO, binding of BH2 completely inhibits the
formation of NO [5] and instead leads to formation of superoxide
[6]; a NOS state referred to as uncoupled. Because of this competi-
tion for binding to NOS, it could be expected that it is the ratio of
BH4-to-BH2 that is important in determining superoxide and NO
production, and hence endothelial dysfunction, rather than the
absolute amount of BH4. Indeed, in a number of studies this asso-
ciation has been observed.
Ascorbate (Asc), the reduced form of vitamin C, is an important
intracellular and circulatory antioxidant and has been suggested to
play an important role in maintaining BH4 in its reduced state.
Thus, in vitro studies have shown that ascorbate selectively reduces
the BH3 radical to BH4, i.e., the one-electron oxidation product
[7,8]. Also, Asc have been suggested to non-selectively spare BH4
from oxidation through its generic antioxidant function [8]. In this
way, Asc may indirectly improve vascular function by increasing
the bioavailability of NO in vivo. In these processes, Asc itself is oxi-
dized to the ascorbyl free radical, two molecules of which dismu-
tate into one molecule of Asc and one of dehydroascorbic acid
(DHA), the fully oxidized form of vitamin C (Fig. 2). In order to pre-
vent loss of vitamin C through oxidation, dehydroascorbic acid is
rapidly reduced to Asc intracellularly by e.g., glutathione or thiore-
doxin reductase in a number of cell types – so called ascorbate
recycling [9]. An intimate relationship between Asc, BH4 and NO
production would provide a rationale partly explaining the signif-
icant relationship between poor vitamin C status and cardiovascu-
lar disease risk that has consistently been reported from large
epidemiological studies [10]. However, until now in vivo and clin-
ical studies investigating this role of Asc have been quite few.
This review discusses the available experimental literature on
the putative role of Asc in NO bioavailability through interactions
with BH4 and NOS.
Biopterin oxidation status as biomarker of endothelial function
A number of studies have pointed out that the ratio of BH4-to-
BH2 may be a better biomarker of superoxide and nitric oxide pro-
duction, and hence endothelial function, than absolute levels of
BH4. Crabtree and co-workers found that NO bioactivity correlated
with intracellular BH4-to-BH2 ratio and not absolute levels of BH4,
and that superoxide production was negatively correlated with
BH4-to-BH2 ratio [4]. Flow-mediated vasodilation was found to
be positively correlated with BH4 plasma levels and negatively cor-
related with BH2 plasma levels in patients with cardiovascular dis-
orders; hence, a very strong positive correlation between ﬂow-
Fig. 1. Structures of tetrahydrobiopterin, dihydrobiopterin, ascorbic acid and dehydroascorbic acid.
Fig. 2. Oxidation of tetrahydrobiopterin to the trihydrobiopterin radical followed by reduction by ascorbate with concomitant formation of the ascorbyl radical, two of which
can dismutate yielding ascorbate and dihydroascorbic acid.
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mediated vasodilation and BH4-to-BH2 ratio was observed [11].
Likewise, in rats treated to increase the amount of BH2 and hence
lower the BH4-to-BH2 ratio, evidence of uncoupling of NOS leading
to increased superoxide production was found [12]. Also, acetyl-
choline-induced vasorelaxation was reduced in the aorta of rats
with lower BH4-to-BH2 ratio and mean blood pressure was found
to be negatively correlated with aortic BH4-to-BH2 ratio [12]. In an-
other study, it was found that both BH4 and BH2 increased in rats
that had undergone arteriovenous ﬁstula (AVF) surgery compared
to sham operated rats [13]. Despite the higher BH4 levels in AVF
rats, superoxide production was increased in AVF rats and this
was attributed to a lower BH4-to-BH2 ratio in these rats [13]. In
ApoE-deﬁcient mice, Asc in the feed decreased the aortic level of
BH2 without inﬂuencing the level of BH4 resulting in an increased
BH4-to-BH2 level which correlated with an increase in NOS activity
[14]. Finally, computational studies conﬁrmed that the ratio of
BH4-to-BH2 is important for the formation of NO and superoxide
from NOS [15].
In vitro studies
As BH4 is easily oxidized, it may easily be envisaged that an
antioxidant—such as vitamin C—may enhance the stability of BH4
and maintain a high ratio of BH4-to-BH2. As expected, Asc has been
shown in several in vitro studies to be able to stabilize BH4. First of
all, the rate of autoxidation of BH4 is dependent on the concentra-
tion of BH4, at least at low pH, which is important to bear in mind
when comparing stability studies performed at different concen-
trations. Thus, 41 nM BH4 was completely converted to BH2 in
15 min at 4 C in 0.1 M HCl, whereas BH4 in a 415 nM solution un-
der the same conditions was only 1% degraded and at higher con-
centrations of BH4 an even smaller percentage was oxidized [16].
Secondly, the stability of BH4 in aqueous solution is dependent
on pH showing increased stability at low pH [3]. In Table 1 is sum-
marized the observed effects of Asc on the stability of BH4 in vitro.
From these studies it seems that the protective effect of Asc is
modest at pH 7.4.
The question is whether the protective effect of Asc is due to Asc
being able to reduce oxidized BH4 or because Asc scavenges reac-
tive oxygen species (ROS) before they react with BH4; or perhaps
both. It is known that Asc is not capable of reducing BH2 [17]. It
has been suggested that Asc could reduce qBH2, the short-lived
intermediate in the oxidation of BH4, though there was no direct
evidence for this mechanism [18–20]. Later on, it was suggested
that thiols may reduce qBH2, while Asc reduces one-electron oxi-
dized BH4 (BH3) [21]. Direct evidence for the reduction of BH3 by
Asc has been obtained by pulse radiolysis [8] and EPR [7] and a rate
constant of 1.7  105 M1 s1 was determined [8].
Whereas an antioxidant activity may easily be demonstrated
in vitro, it is much more difﬁcult to prove that the reaction is also
relevant in vivo. BH4 bound to NOS does become oxidized to BH3
during the catalytic cycle of NOS [22]. However, reduction of BH3
to BH4 is performed by NOS and does not involve Asc [22]. Whether
freely circulating BH4 once oxidized is actually reduced by Asc
in vivo remains to be established.
The second possibility that Asc protects BH4 from oxidation by
scavenging ROS has also been explored. The ROS of particular rel-
evance are superoxide, as it is formed by NOS when uncoupled,
and peroxynitrite as it is formed by reaction between NO, the prod-
uct of NOS, and superoxide. Superoxide reacts rather slowly with
both ascorbate and BH4 with a rate contant of 3–4  105 M1 s1
[17,23]. Superoxide, on the other hand, reacts rapidly with NO with
a rate constant of the order of 109–1010 M1 s1 [24–26] to produce
peroxynitrite. Peroxynitrite has been shown to react 6–10 times
faster with BH4 than with Asc [7]. Thus, in order for Asc to protect
BH4 from oxidation by peroyxnitrite in vivo, Asc must be present at
a much higher concentration than BH4. The micromolar concentra-
tion of Asc in plasma should be able to protect the nanomolar con-
centration of BH4 from oxidation by these two ROS. Inside
endothelial cells the concentration of BH4 has been determined
to be a few pmol/mg protein [20,27,28]. Again, the much higher
intracellular concentration of Asc compared to BH4—about three
orders of magnitude [29–31]—means that Asc could kinetically
protect BH4, but other systems such as superoxide dismutase
may play a more prominent role in vivo.
Ex vivo studies
Concerning the interaction between Asc and BH4, three types of
ex vivo studies have been performed: (1) studies involving NOS iso-
lated from tissue, (2) studies involving cell cultures and (3) studies
involving isolated tissues or organs. The primary focus of these
studies has been to elucidate the mechanisms by which Asc may
increase the bioavailability of NO.
Nos
Asc was found to increase the activity of iNOS as measured by
the formation of L-citrulline, whereas dehydroascorbic acid at con-
centrations higher than 1 mM decreased the activity of iNOS [32].
It was suggested that this was due to an antioxidant effect of Asc,
in line with the ﬁnding that Asc also decreased the apparent S0.5
value (the concentration at which the enzyme has half its maximal
activity) of BH4 [32], i.e., less BH4 is needed if it’s not becoming oxi-
dized. Similarly, another study found that Asc increased the activ-
ity of eNOS in a concentration-dependent manner, as measured by
Table 1
Effect of Asc on the stability of BH4 in vitro.
BH4 concentration (lM) Asc concentration (lM) Observation Conditions Reference
32.13 0 88% Breakdown 20 h, 4 C, 0.1 M HCl [16]
32.13 5700 0% Breakdown 20 h, 4 C, 0.1 M HCl, Ar
0.0415 5700 0% Breakdown 4 h, 4 C, 0.1 M HCl, Ar
0.1 0 100% Breakdown 20 min, RT, pH 7.4 [20]
0.1 100 Half-life around 70 min RT, pH 7.4
25 0 53% Breakdown 1 h, 22 C, pH 7.4 [18]
25 500 46% Breakdown 1 h, 22 C, pH 7.4
25 1500 35% Breakdown 1 h, 22 C, pH 7.4
25 3000 7% Breakdown 1 h, 22 C, pH 7.4
20 0 100% Breakdown 0 h, 37 C, pH 7.4 [38]
20 500 60% Breakdown 21 h, 37 C, pH 7.4
36 0 Half-life 17.5 min 0.5 mM EDTA, 26 C, pH 7.4 [19]
36 100 Half-life around 25 min 0.5 mM EDTA, 26 C, pH 7.4
RT: room temperature.
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the formation of L-citrulline [28]. BH4 was also found to increase
the activity of eNOS, as measured by the formation of L-citrulline,
in microsomes prepared from human placental tissue; here, Asc
enhanced the effect of BH4 on eNOS by an additional 40% [18].
Cells
The cell types that have been studied are primarily endothelial
cells but other cell types have been studied as well. Several studies
have found that Asc enhanced the activity of NOS in intact cells. In-
creased formation of L-citrulline in the presence of Asc is often used
as a biomarker of enhanced NOS activity [20,28,33–37]. Other
ways of assessing the activity of NOS in the presence of Asc are for-
mation of nitrite and nitrate, oxidation products of NO
[28,34,38,39], direct detection of NO [37] or cGMP, the latter
formed by action of NO on soluble guanylate cyclase [33].
Several studies have found that Asc dose-dependently increased
NO bioavailability and BH4 levels in endothelial cells (Table 2). It
was found that Asc did not induce NOS expression in endothelial
cells [28,33,35,39] or in macrophages [38]. Likewise, it was found
that Asc did not induce increased biosynthesis of BH4 [20,38] nor
did Asc change the afﬁnity of NOS towards BH4 [20]. The increase
in BH4 was hence ascribed ‘a stabilizing effect’ of Asc on BH4 [20].
Also, Asc did not enhance the cellular uptake of L-arginine [33], the
substrate of NOS, nor did it change the Km of L-arginine [28].
An increase in intracellular BH4 levels increased NO bioavail-
ability [20,28,35]. The observed increase in BH4 levels induced by
Asc may hence explain the increased NO bioavailability caused
by Asc (Table 2). In addition to this effect of Asc, another mecha-
nism has been suggested that enhances NO production without
increasing BH4 levels. It was found that Asc increased phosphory-
lation of eNOS-Ser1177 and decreased phosphorylation of eNOS-
Thr495 and this correlated with an increased eNOS activity [36].
Intracellular BH4 levels did not increase until after four hours,
but the increase in eNOS activity was seen already after 2–4 h incu-
bation with Asc, and it was concluded that Asc may rapidly in-
crease eNOS activity by phosphorylation/dephosphorylation and
long-term by increasing BH4 levels [36].
Another potential mechanism involving eNOS activity has been
proposed. Just like phosphorylation controls eNOS activity, so does
S-nitrosylation. In a study, it was shown that S-nitrosylation inhib-
its eNOS activity in endothelial cells, and that eNOS S-nitrosylation
correlated inversely with eNOS-Ser1177 phosphorylation [40]. Incu-
bation of puriﬁed eNOS with Asc enhanced eNOS activity by 20%
which correlated with a lower degree of eNOS S-nitrosylation
[40] – the effect could not have been due to changes in phosphor-
ylation status, as this requires the presence of phosphorylating en-
zymes [36]. Unfortunately, the effect of Asc on BH4 levels was not
examined in this study.
Besides endothelial cells, the effect of Asc on NOS activity has
been studied in cells of the immune system. In contrast to endothe-
lial cells, which contain eNOS, cells of the immune system contain
iNOS and nNOS [37]. Neutrophils from guinea pigs on an ascorbic
acid-deﬁcient diet for two weeks were found to contain less Asc
and BH4 and have lower eNOS activity compared to neutrophils
from control animals [37]. The expression of iNOS and nNOS was
lower in neutrophils from Asc-deﬁcient guinea pigs [37], whereas
in endothelial cells, Asc did not inﬂuence eNOS expression (see
above). Another study did not observe any changes in iNOS expres-
sion in mouse macrophage RAW 264.7 cells incubated with Asc, in
contrast to a previous study that found a 2-fold increase in iNOS
levels in mouse macrophage J774.1 cells [41], but did ﬁnd an in-
crease in BH4 level and NOS activity [38]. Likewise, Asc in aqueous
humor was found to increase nitrite formation in mice macro-
phages, an effect that was ascribed to a stabilizing effect on BH4 ob-
served in the growth medium [42]. In polymorphonuclear
leukocytes, both Asc and DHA were found to increase NOS activity
[34].
Tissues and organs
A couple of studies have looked at the effect of Asc and BH4 on
isolated tissues and organs. In excised aortas from rats, in which
NOS had been inhibited in vivo by Nx-nitro-L-arginine, sepiapterin,
a precursor of BH4, was found to reduce vasodilation in contrast to
what might be expected. The reduced vasodilation was believed to
be due to autoxidation of BH4 caused by increased oxidative stress
[43]. Incubation of the aortic rings with Asc (1 lM) for 10 min re-
stored vasodilation and this was suggested to be due to Asc stabi-
lizing BH4 [43]. In another study, ascorbic acid (10 g/kg chow) was
given to wild-type and ApoE-deﬁcient mice for 26–28 weeks.
Whereas Asc increased acetylcholine-induced vasorelaxation in
ApoE-deﬁcient mice, it reduced vasorelaxation in wild-type mice
[14]. In aortic homogenate, Asc in the diet increased L-citrulline
formation in both wild-type and ApoE-deﬁcient mice without
affecting NOS expression, in line with the ﬁndings in endothelial
cells (see above). Again, protection of BH4 by Asc was suggested
to explain the ﬁndings [14]. The activity of eNOS and nNOS in-
creased while iNOS activity decreased in ischemic rat muscle
homogenate from rats fed BH4, L-arginine and Asc (alone or in com-
bination) with the largest change seen in the BH4 + L-arginine + Asc
group [44]. This correlated with an increased eNOS expression and
NO production found in vivo (see below). Okazaki et al. induced
diabetes in rats and their hearts were isolated and perfused. BH4
and the BH4-to-BH2 ratio were decreased in the diabetic hearts
whereas superoxide increased. Treatment with Asc increased the
BH4-to-BH2 ratio, decreased superoxide production and increased
nitrite and nitrate [45].
Table 2
Effect of Asc on eNOS activity and intracellular BH4 levels in endothelial cells.
Cells Extracellular Asc
(lM)
Intracellular Asc pmol/mg
protein
Effect on BH4 Effect on NO bioavailability Reference
HUVEC 0.1–100 21,500 n.d. 3-Fold increase in L-citrulline and cGMP [33]
PAEC 75 20,000 Increased 126% 59–73% Increase in cGMP, L-citrulline and nitrite/
nitrate
[28]
HUVEC 1–1000 n.d. 3-Fold increase Dose-dependent increase of L-citrulline [20]
HUVEC 100 n.d. 1.9-Fold increase 50% Increase in L-citrulline [35]
HUVEC 100 n.d. 23% (Not
signiﬁcant)
n.d. [54]
BAEC n.d. 20–430 20% Increase 2-Fold increase of nitrite/nitrate [39]
HUVEC
EA.hy926
100 4000 56% Increase 50% Increase in L-citrulline [36]
HUVEC: human umbilical vein endothelial cell; n.d.: not determined; PAEC: porcine aortic endothelial cell; BAEC: bovine aorta endothelial cells.
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Asc enhancement of eNOS activity
Based on the in vitro and ex vivo ﬁndings, the effect of Asc on
eNOS activity may be summarized as in Fig. 3. Besides the reac-
tions depicted in Fig. 3, Asc might also increase NO bioavailability
in an eNOS-independent reaction by reducing nitrite, a degradation
product of NO, to NO, a process utilized in the curing of meat. How-
ever, this reaction requires a low pH, such as that found in the
stomach, to proceed at an appreciable rate [46]. Hence, in the vas-
culature, enzymatic reduction of nitrite to NO is more likely than
Asc-mediated reduction [47].
In vivo studies
Many studies have looked at the effect of either BH4 or Asc on
endothelial function (for recent reviews see [1,48]. These studies
have collectively shown that Asc and BH4 may individually in-
crease the bioavailability of NO in vivo and improve clinical end
points such as blood pressure and blood ﬂow. However, this review
will focus on studies in which BH4 and Asc have been administered
and/or assayed together. Such combined experiments have been
performed in both humans and animals. Whereas experiments in
humans have mainly looked at clinical endpoints, animal experi-
ments have mostly been concerned with measurements of NOS
activity.
Animals
Guinea pigs, like humans, lack the ability to synthesize Asc and
therefore completely rely on its presence in their diet [49]. Conse-
quently, the guinea pig is a particularly well-suited animal model
to study the possible interaction between vitamin C and BH4. Chat-
terjee and coworkers placed guinea pigs on a vitamin C deﬁcient
diet for two weeks and found that, Asc in plasma and in neutro-
phils decreased by 80% and 78%, respectively, compared to guinea
pigs supplemented with 30 mg/day [37]. As a result of the ascorbic
acid-deﬁcient diet, BH4 levels in neutrophils decreased by 60% [37].
The neutrophils were isolated and used for ex vivo studies (see
above). Recently, we have demonstrated that plasma biopterin oxi-
dation status is closely linked to the amount of Asc in plasma and
hence in the diet in vivo [50]. In another study, guinea pigs were
fed a diet containing either 100, 250, 500, 750, 1000 or
1500 ppm ascorbic acid. Those receiving 500–1500 ppm Asc had
signiﬁcantly higher plasma levels of BH4, than those receiving
100 ppm and the group fed 100 ppm Asc also had a higher BH2-
to-BH4 ratio than all the other groups [50]. A positive linear corre-
lation between plasma BH4 and plasma Asc was observed, whereas
a negative correlation was observed between plasma BH4 and plas-
ma DHA. BH2 plasma levels were not correlated with either Asc or
DHA, whereas the BH4-to-BH2 ratio showed the same correlations
as did BH4 [50].
Commonly used rodents such as mice and rats produce their
own vitamin C thereby potentially making supplementation stud-
ies difﬁcult to interpret. Regardless, studies have also investigated
the relationship between Asc and BH4 in these species. Similarly to
the guinea pigs studies mentioned above, wild-type mice receiving
feed containing 1% Asc more than tripled their BH4 in aorta with no
effect on BH2 levels compared to controls [14]. In ApoE-deﬁcient
mice, on the other hand, BH4 levels in aorta were unaffected by
supplementation with Asc, while BH2 levels decreased; however,
neither BH4 nor BH2 levels in liver were affected by vitamin C sup-
plementation [14]. In both cases, this resulted in an increased BH4-
to-BH2 ratio which correlated with increased NOS activity as mea-
sured by the formation of L-citrulline [14].
Other studies have looked at the effect of increased bioavailabil-
ity of Asc and BH4. Rats received BH4, L-arginine, BH4 + L-arginine
or BH4 + L-arginine + ascorbic acid in their diet for one week after
which hindlimb ischemia was induced. The rats fed either BH4 or
L-arginine alone showed no improvement of blood ﬂow recovery
after induction of ischemia whereas those receiving either
BH4 + L-arginine or BH4 + L-arginine + Asc showed a signiﬁcant
improvement [44]. This correlated with an increase in collateral ar-
tery diameter in rats receiving BH4 + L-arginine with an even great-
er increase when Asc was also included in the feed. Nitrite and
nitrate, markers of NO, were higher in rats fed BH4 + L-arginine
and BH4 + L-arginine + Asc, and inclusion of Asc in the diet caused
higher levels of nitrite and nitrate though it did not reach statistical
signiﬁcance (compared to the BH4 + L-arginine group), which cor-
related with an increase in eNOS expression [44]. Oxidative stress,
measured as nitrotyrosine and ratio of glutathione to glutathione
disulﬁde, was also lowest in the group receiving Asc [44]. In an-
other study, ApoE-knockout mice overexpressing eNOS (leading
to increased oxidative stress) were crossed with mice overexpress-
ing the rate-limiting enzyme in the biosynthesis of BH4. This group
was compared to ApoE-knockout mice overexpressing eNOS and to
ApoE-knockout mice overexpressing eNOS who were given 500 mg
ascorbic acid/kg body weight/day [51]. The effect of increased BH4
biosynthesis was an increase in BH4 in aorta but without a con-
comitant increase in BH4-to-BH2 ratio; Asc had no effect on BH4
levels or BH4-to-BH2 ratio. BH4 increased the eNOS dimer-to-
monomer ratio and decreased superoxide concentrations – Asc
also decreased superoxide concentration but without altering the
eNOS dimer-to-monomer ratio [51], indicating that Asc scavenges
superoxide rather than changing the propensity for eNOS to pro-
duce superoxide. Overexpression of BH4 led to a decrease in ath-
erosclerotic lesion formation whereas supplementing with Asc
had no effect on atherosclerotic lesion formation in ApoEmice [51].
Clinical studies
For years, epidemiological studies have repeatedly shown that a
poor vitamin C status is associated with increased risk of develop-
ing cardiovascular disease [52]. Fueled by the expanding in vitro
literature supporting a role of Asc in maintaining BH4 reduced,
we and others have speculated that increased NO availability med-
iated by reducing equivalents from Asc may be the missing link
explaining the clinical observations [52]. However, so far only a
very limited number of clinical studies have investigated the rela-
tionship between Asc and BH4.
In one study, people suffering from hypertension (systolic blood
pressure >135 mmHg) were given an oral combination of BH4 and
Asc (200 mg of each twice daily or 100 mg of each twice daily for
four weeks). A signiﬁcant decrease in systolic and mean blood
pressure and an increase in ﬂow-mediated vasodilation were ob-
Fig. 3. Mechanisms by which Asc may improve vasorelaxation by increasing NO
bioavailability through increased eNOS activity. See text for details.
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served [53]. The effect on blood pressure was ascribed to BH4 as a
two week run-in period with Asc alone did not alter blood pres-
sure. However, a combination effect of BH4 and Asc could not be
ruled out [53].
Mittermayer and co-workers studied the effect of BH4 and Asc
on forearm blood ﬂow (FBF) responses to acetylcholine. Infusion
of lipopolysaccharide caused a decrease in FBF response to acetyl-
choline of 23%, but subsequent infusions of BH4 (500 lg/min) or
Asc (24 lg/min) restored FBF response to baseline values [54].
Asc did not increase systemic levels of BH4 but did cause a local
BH4 increase in the forearm [54]. In a similar study, the effect of
BH4 and Asc on FBF in chronic smokers was examined. BH4 infusion
(500 lg/min) increased FBF response to acetylcholine and seroto-
nin in smokers but not in non-smokers; Asc infusion (6 or 18 lg/
min) also improved FBF response to acetylcholine (the response
to serotonin was not examined) [55]. Co-infusion of BH4 and Asc
did not improve FBF compared to either agent alone and infusion
of Asc prior to infusion of BH4 abolished the effect of BH4 [55].
As reviewed in detail elsewhere [48], vitamin C pharmacokinet-
ics are highly dose dependent and ingestion of about 400 mg/day
result in a situation of near-saturation of plasma and tissues [10].
Thus, if adequately supplied through the diet, excess amounts
achieved, e.g., by supplementation, are rapidly and effectively ex-
creted. As discussed below, this issue is often overlooked in the
clinical literature on vitamin C supplementation [56], and notably,
none of the studies mentioned above enrolled subjects that were
vitamin C deﬁcient at study start. Consequently, they give no infor-
mation on whether poor vitamin C status—a situation affecting
substantial proportions of the World’s population including the
industrialized parts [56]—negatively affects the bioavailability of
BH4 or if poor BH4 status can be ameliorated by vitamin C
supplementation.
Looking more generally at cardiovascular health, almost all of
the large phase III randomized controlled trials using vitamin C
as intervention have not been able to demonstrate effect of vitamin
C supplementation on cardiovascular morbidity or mortality [57–
61]. This constitutes a considerable discrepancy to the experimen-
tal and epidemiological literature. However, while experimental
and epidemiological literature is generally weakened by their
insufﬁcient predictive validity, lack of ability to demonstrate cau-
sality in humans, and risk of unidentiﬁed confounders and co-deﬁ-
ciencies, the majority of the large clinical intervention studies
suffers from several serious design issues including e.g., absence
of vitamin C deﬁciency as inclusion criterion, no record of vitamin
C status before or after intervention, and unrecorded concurrent
supplementation with vitamin C – also among placebo allocated
individuals [52]. Thus, based on the information provided, the ma-
jor vitamin C intervention studies with cardiovascular endpoints
have the serious weakness of studying populations with adequate
to high vitamin C levels at baseline. This renders them only able to
conﬁrm that supplementation to already well-nourished individu-
als is very likely to be without effect. Unfortunately, no trials have
so far systematically studied the effect of vitamin C deﬁciency on
cardiovascular risk or the effect of supplementation in this partic-
ularly relevant subpopulation. Consequently, it is not presently
possible to evaluate to what extend the potential effects of vitamin
C on BH4 status found experimentally are clinically relevant.
Conclusion
Asc has been shown to improve vasorelaxation in humans and
animals. A number of studies have indicated that rather than a sin-
gle mechanism, several different mechanisms appear to be in-
volved in Asc-mediated vasorelaxation. Mainly, Asc may improve
endothelial function by increasing NO bioavailability through BH4
and eNOS. Asc may increase BH4 bioavailability by protecting
BH4 from being oxidized by scavenging ROS and/or by reducing
oxidized BH4. Asc may also increase eNOS activity by changing
its phosphorylation and S-nitrosylation status. However, although
shown to occur ex vivo, it remains to be established to which extent
these mechanisms are important in vivo.
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